Metropolitan Life Insurance Company (MetLife)’s Esperion Therapeutics ESPR Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,032	Closed	-$25.1K	–	2357
2022 Q4	$25.1K	Hold	4,032	–	–	﹤0.01%	1882
2022 Q3	$27K	Buy	4,032 +1,675	+71%	+$11.5K	﹤0.01%	1853
2022 Q2	$15K	Sell	2,357 -1,757	-43%	-$9.96K	﹤0.01%	2184
2022 Q1	$19.1K	Buy	+4,114	New	+$17.6K	﹤0.01%	2118
2021 Q4	–	Sell	-7,777	Closed	-$93.7K	–	2801
2021 Q3	$93.7K	Hold	7,777	–	–	﹤0.01%	2559
2021 Q2	$164K	Hold	7,777	–	–	﹤0.01%	2294
2021 Q1	$218K	Hold	7,777	–	–	﹤0.01%	1958
2020 Q4	$202K	Hold	7,777	–	–	﹤0.01%	1930
2020 Q3	$289K	Hold	7,777	–	–	﹤0.01%	1561
2020 Q2	$399K	Hold	7,777	–	–	0.01%	1374
2020 Q1	$245K	Hold	7,777	–	–	0.01%	1474
2019 Q4	$464K	Sell	7,777 -1,452	-16%	-$65.3K	0.01%	1372
2019 Q3	$338K	Buy	9,229 +1,531	+20%	+$60.6K	0.01%	1531
2019 Q2	$358K	Hold	7,698	–	–	0.01%	1507
2019 Q1	$309K	Hold	7,698	–	–	0.01%	1610
2018 Q4	$354K	Hold	7,698	–	–	0.01%	1434
2018 Q3	$342K	Hold	7,698	–	–	0.01%	1644
2018 Q2	$302K	Buy	7,698 +2,224	+41%	+$112K	﹤0.01%	1656
2018 Q1	$396K	Hold	5,474	–	–	0.01%	1433
2017 Q4	$360K	Sell	5,474 -5,422	-50%	-$292K	﹤0.01%	1504
2017 Q3	$546K	Hold	10,896	–	–	﹤0.01%	1637
2017 Q2	$504K	Hold	10,896	–	–	﹤0.01%	1684
2017 Q1	$385K	Buy	+10,896	New	+$250K	﹤0.01%	1840
2016 Q3	–	Sell	-9,258	Closed	-$91K	–	2641
2016 Q2	$91K	Hold	9,258	–	–	﹤0.01%	2602
2016 Q1	$157K	Hold	9,258	–	–	﹤0.01%	2315
2015 Q4	$206K	Hold	9,258	–	–	﹤0.01%	2250
2015 Q3	$218K	Hold	9,258	–	–	﹤0.01%	2231
2015 Q2	$757K	Buy	9,258 +3,951	+74%	+$387K	0.01%	1477
2015 Q1	$491K	Hold	5,307	–	–	﹤0.01%	1573
2014 Q4	$215K	Buy	+5,307	New	+$162K	﹤0.01%	2367

Other funds holding ESPR

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ESPR Position: Q1 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Esperion Therapeutics (ESPR) in Q1 2023, closing a stake of 4,032 shares — an estimated $25.1K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ESPR in Q4 2014 and held it in 30 quarters. The position peaked at $757K in Q2 2015. 164 funds tracked by Wall St. Rank hold ESPR as of Q1 2023.

Metropolitan Life Insurance Company (MetLife) reported no remaining Esperion Therapeutics position as of Q1 2023 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 4,032 Esperion Therapeutics shares in Q1 2023, an estimated $25.1K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Esperion Therapeutics in Q4 2014 and held it in 30 quarters.
Metropolitan Life Insurance Company (MetLife)'s Esperion Therapeutics position peaked at $757K in Q2 2015.
164 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2023, filed 15 May 2023.